FP Pharmaceutical

FP Pharmaceutical Corporation is a Japanese pharmaceutical company specializing in the development and commercialization of treatments for neurological and psychiatric disorders, with a primary focus on Parkinson's disease. A sister company of Fujimoto Pharmaceutical Corporation, it is best known for introducing selegiline hydrochloride (an MAO-B inhibitor) to the Japanese market in 1998. The company's flagship product is the FP-OD Tablet, an orally disintegrating formulation of selegiline designed to improve patient compliance. FP Pharmaceutical is actively involved in clinical research, including the development of FPF1100NW for early-stage Parkinson's disease. The company maintains a strong presence in the Japanese movement disorder sector and collaborates with academic institutions and global partners to address unmet medical needs in neurodegeneration. It operates as part of the Fujimoto Pharmaceutical Group, leveraging shared resources for R&D and manufacturing.